ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Whole-Body MRI Helps Predict CVD Burden in Diabetes Patients
Findings independent of other established clinical or laboratory markers

THURSDAY, Sept. 12 (HealthDay News) -- Whole-body magnetic resonance imaging (MRI) predicts cardiac and cerebrovascular disease burden in patients with diabetes mellitus (DM), according to a study published online Sept. 10 in Radiology.

Fabian Bamberg, M.D., M.P.H., from Ludwig Maximilians University in Munich, and colleagues evaluated 61 patients (median age, 67.5 years; 30 women) with DM (types 1 and 2), including a follow-up phone interview (median follow-up, 70 months). Patients underwent a comprehensive, contrast-enhanced whole-body MRI protocol, including brain, cardiac, and vascular sequences at baseline, which were evaluated for the presence of systemic atherosclerotic vessel changes, white matter lesions, and myocardial changes. A major adverse cardiac and cerebrovascular event (MACCE) was the primary end point.

The researchers found that 14 of the 61 patients experienced MACCE. Two-thirds of patients had any detectable ischemic and/or atherosclerotic changes at whole-body MRI, which conferred a cumulative event rate of 20 percent at three years and 35 percent at six years. The absence of pathologic findings on imaging was associated with a zero event probability. A summary estimate of disease using whole-body MRI was strongly predictive for MACCE (one increment of vessel score hazard ratio, 13.2; each territory with atherosclerotic changes hazard ratio, 3.9), beyond clinical characteristics as well as individual cardiac or cerebrovascular MRI findings.

"These initial data indicate that disease burden as assessed with whole-body MRI confers strong prognostic information in patients with DM," the authors write.

Several authors disclosed financial ties to Bayer Healthcare and/or Siemens Healthcare.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS